Paclitaxel wafer during lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new way of giving paclitaxel—a chemotherapy drug—directly into the chest during lung cancer surgery. It aims to reduce the chance of cancer coming back after surgery, and may have fewer side effects than standard IV chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (a common type of lung cancer) that is early stage and can be removed with surgery.
- You are 18 or older and your doctor agrees you can have surgery to remove the cancer.
- You have not had chemotherapy or radiation therapy before this surgery.
- Your blood counts, liver, and kidney function are within healthy ranges.
- You are willing to use highly effective birth control if pregnancy is possible.
- You are able to follow the study schedule and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral form of the chemotherapy drug paclitaxel given before surgery for elderly patients with non-small cell lung cancer. The goal is to see if it helps shrink tumors and improve outcomes with fewer side effects than IV chemotherapy.
This trial gives weekly paclitaxel chemotherapy before breast surgery, then studies tumor “biomarkers” to see how well treatment is working. The goal is to improve how doctors predict which patients benefit and who may need different approaches.
This trial tests a new way of giving radiation (in high and low doses) together with chemotherapy and immunotherapy to treat advanced non-small cell lung cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
This trial tests a new way to treat non-small cell lung cancer in people aged 70 or older. You will receive oral chemotherapy (paclitaxel) with immunotherapy and focused radiation (SBRT) before surgery, hoping to shrink the tumor and improve outcomes.
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
Hear when a new Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.